Avodart: Treatment of benign prostatic hyperplasia

Indication

Treatment and prevention of the progression of benign prostatic hyperplasia (to reduce the size of the prostate, relieve symptoms, improve urination and reduce the risk of acute urinary retention and the need for surgical treatment). The drug inhibits the activity of isozymes 5?-reductase types 1 and 2, which are responsible for the conversion of testosterone to 5?-dihydrotestosterone. Avodart in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate.

Dosage and administration

Dutasteride can be used as a single agent and in combination with alpha 1-adrenergic antagonist.

Avodart can be taken with or without food.

The drug takes effect quickly, but treatment should be continued for at least 6 months to evaluate objectively the effect of the drug.

For adult men, including elderly patients, the recommended dose oral is 500 mg (1 capsule). 1 time / day. The capsules should be swallowed whole, do not chew or open, as the contents of the capsules can cause irritation of the oropharynx.

Combination with alpha adrenergic antagonist: the recommended dose of avodart is 1 capsule (0.5 mg) 1 time / day and tamsulosin 0.4 mg taken once daily.

For patients with renal impairment the adjustment of the dose is not required.

The patients with impaired liver function should be used the drug with caution, as dutasteride is subjected to intensive metabolism in the liver.